Police & Firemen s Retirement System of New Jersey Has $1.63 Million Position in Roivant Sciences Ltd. $ROIV

Police & Firemen s Retirement System of New Jersey cut its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 4.6% during the second quarter, Holdings Channel.com reports. The fund owned 144,919 shares of the company’s stock after selling 6,958 shares during the period. Police & Firemen s Retirement System of New Jersey’s holdings in Roivant Sciences were worth $1,633,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Roivant Sciences by 10.0% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 102,478 shares of the company’s stock valued at $1,034,000 after purchasing an additional 9,357 shares during the period. Corton Capital Inc. bought a new stake in Roivant Sciences in the first quarter valued at about $111,000. XTX Topco Ltd lifted its stake in Roivant Sciences by 634.1% in the first quarter. XTX Topco Ltd now owns 256,714 shares of the company’s stock valued at $2,590,000 after buying an additional 221,742 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Roivant Sciences by 44.8% during the first quarter. PNC Financial Services Group Inc. now owns 10,248 shares of the company’s stock worth $103,000 after buying an additional 3,169 shares during the last quarter. Finally, New Age Alpha Advisors LLC boosted its holdings in Roivant Sciences by 37.1% during the first quarter. New Age Alpha Advisors LLC now owns 21,966 shares of the company’s stock worth $222,000 after buying an additional 5,943 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on ROIV shares. HC Wainwright increased their price target on shares of Roivant Sciences from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, September 18th. Bank of America upped their target price on shares of Roivant Sciences from $12.00 to $16.50 and gave the company a “neutral” rating in a research note on Thursday, September 18th. Citigroup boosted their price target on shares of Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. The Goldman Sachs Group raised their price objective on Roivant Sciences from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, September 18th. Finally, Leerink Partners reissued an “outperform” rating and issued a $29.00 target price on shares of Roivant Sciences in a research note on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $22.56.

Roivant Sciences Stock Down 0.3%

Shares of NASDAQ:ROIV opened at $20.27 on Friday. The firm has a market cap of $13.84 billion, a price-to-earnings ratio of -36.20 and a beta of 1.23. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $21.35. The company’s fifty day simple moving average is $17.54 and its 200 day simple moving average is $13.58.

Insider Activity

In other news, CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $20.22, for a total transaction of $4,044,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,504,959 shares of the company’s stock, valued at $30,430,270.98. This trade represents a 11.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Vivek Ramaswamy sold 539,650 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $20.51, for a total transaction of $11,068,221.50. Following the completion of the transaction, the insider directly owned 33,653,756 shares of the company’s stock, valued at approximately $690,238,535.56. This trade represents a 1.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 7,183,561 shares of company stock worth $117,258,750 in the last three months. Company insiders own 10.80% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.